Monitoring Response to Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Using High-speed MR Spectroscopic Imaging
Condition(s):HER2 Negative Breast CancerLast Updated:January 11, 2024Recruiting
Include Studies Not Open or Pending
Condition(s):HER2 Negative Breast CancerLast Updated:January 11, 2024Recruiting
Condition(s):Breast CancerLast Updated:January 10, 2024Not yet recruiting
Condition(s):HER2-negative Breast CancerLast Updated:March 3, 2022Not yet recruiting
Condition(s):HER2-negative Breast Cancer; Advanced Solid TumorLast Updated:April 18, 2023Recruiting
Condition(s):Luminal B/HER2-negative Breast CancerLast Updated:January 31, 2024Recruiting
Condition(s):HER2-negative Breast Cancer; Triple Negative Breast CancerLast Updated:March 2, 2023Recruiting
Condition(s):Breast Cancer; MelanomaLast Updated:March 6, 2024Recruiting
Condition(s):Locoregional Recurrence; Hormone Receptor-positive Breast Cancer; HER2-negative Breast CancerLast Updated:January 5, 2024Recruiting
Condition(s):HER2-negative Breast Cancer; Leptomeningeal MetastasisLast Updated:March 26, 2024Recruiting
Condition(s):Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment FailedLast Updated:November 15, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.